Global Alpha-1 Antitrypsin Drugs Market 2018-2022

α1-アンチトリプシン薬の世界市場2018-2022

◆タイトル:Global Alpha-1 Antitrypsin Drugs Market 2018-2022
◆商品コード:IRTNTR21835
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2018年8月20日
◆ページ数:107
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル、アジア、北米、ヨーロッパ(EMEA)
◆産業分野:医療・製薬・バイオ
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,500 ⇒換算¥395,500見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD5,000 ⇒換算¥565,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、α1-アンチトリプシン薬の世界市場について調査・分析し、市場概要、市場環境、α1-アンチトリプシン薬市場規模、投与経路別(非経口、吸入)分析、市場動向、競争環境、主要地域別市場規模(北米、ヨーロッパ、アジアなど)、関連企業情報などを含め、以下の構成でお届け致します。主な分析対象企業は、Shire, CSL, GRIFOLS, and Kamadaなどです。
・エグゼクティブサマリー
・調査範囲・調査手法
・α1-アンチトリプシン薬の世界市場概要
・α1-アンチトリプシン薬の世界市場環境
・α1-アンチトリプシン薬の世界市場動向
・α1-アンチトリプシン薬の世界市場規模
・α1-アンチトリプシン薬の世界市場:業界構造分析
・α1-アンチトリプシン薬の世界市場:投与経路別(非経口、吸入)
・α1-アンチトリプシン薬の世界市場:地域別市場規模・分析
・α1-アンチトリプシン薬の北米市場規模・予測
・α1-アンチトリプシン薬のヨーロッパ・中東・アフリカ市場規模・予測
・α1-アンチトリプシン薬のアジア太平洋市場規模・予測
・α1-アンチトリプシン薬の主要国分析
・α1-アンチトリプシン薬の世界市場:意思決定フレームワーク
・α1-アンチトリプシン薬の世界市場:成長要因、課題
・α1-アンチトリプシン薬の世界市場:競争環境
・α1-アンチトリプシン薬の世界市場:関連企業情報(ベンダー分析)

About Alpha-1 Antitrypsin Drugs
Alpha-1 antitrypsin augmentation therapy is used for treating emphysema caused due to deficiency of alpha-1 antitrypsin proteins in the bloodstream.
Technavio’s analysts forecast the Global Alpha-1 Antitrypsin Drugs Market to grow at a CAGR of 10.64% during the period 2018-2022.

Covered in this report
The report covers the present scenario and the growth prospects of the alpha-1 antitrypsin drugs market. To calculate the market size, the report considers the revenue generated from the sales of alpha-1 antitrypsin drugs across the globe.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, alpha-1 antitrypsin drugs market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
• Shire
• CSL
• GRIFOLS
• Kamada
Market driver
• Improving diagnosis of alpha-1 antitrypsin deficiency
• For a full, detailed list, view our report

Market challenge
• High cost of drugs
• For a full, detailed list, view our report

Market trend
• Strategic alliances and mergers
• For a full, detailed list, view our report

Key questions answered in this report
• What will the market size be in 2022 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【資料の目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 05: MARKET SIZING
• Market definition
• Market sizing 2017
• Market size and forecast 2017-2022
PART 06: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 07: MARKET SEGMENTATION ROUTE OF ADMINISTRATION
• Segmentation by route of administration
• Comparison by Route of Administration
• Parenteral – Market size and forecast 2017-2022
• Inhalation
• Market opportunity by RoA
PART 08: CUSTOMER LANDSCAPE
PART 09: REGIONAL LANDSCAPE
• Geographical segmentation
• Regional comparison
• Americas – Market size and forecast 2017-2022
• EMEA – Market size and forecast 2017-2022
• APAC – Market size and forecast 2017-2022
• Market opportunity
PART 10: DECISION FRAMEWORK
PART 11: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 12: MARKET TRENDS
PART 13: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 14: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• CSL
• GRIFOLS
• Kamada
• Shire
PART 15: PIPELINE ANALYSIS
• Pipeline analysis
PART 16: APPENDIX
• List of abbreviations

Exhibit 01: Global alpha-1 antitrypsin drugs market – Market characteristics
Exhibit 02: Global alpha-1 antitrypsin drugs market – Market segments
Exhibit 03: Global alpha-1 antitrypsin drugs market – Market definition – Inclusions and exclusions checklist
Exhibit 04: Global alpha-1 antitrypsin drugs market – Market size 2017
Exhibit 05: Validation techniques employed for market sizing 2017
Exhibit 06: Global alpha-1 antitrypsin drugs market – Market size and forecast 2017-2022 ($ mn)
Exhibit 07: Global alpha-1 antitrypsin drugs market – Year-over-year growth 2018-2022 (%)
Exhibit 08: Five forces analysis 2017
Exhibit 09: Five forces analysis 2022
Exhibit 10: Global alpha-1 antitrypsin drugs market – Bargaining power of buyers
Exhibit 11: Global alpha-1 antitrypsin drugs market – Bargaining power of suppliers
Exhibit 12: Global alpha-1 antitrypsin drugs market – Threat of new entrants
Exhibit 13: Global alpha-1 antitrypsin drugs market – Threat of substitutes
Exhibit 14: Global alpha-1 antitrypsin drugs market – Threat of rivalry
Exhibit 15: Market condition – Five forces 2017
Exhibit 16: Route of Administration – Market share 2017-2022 (%)
Exhibit 17: Comparison by Route of Administration
Exhibit 18: Parenteral RoA – Market size and forecast 2017-2022 ($ mn)
Exhibit 19: Parenteral RoA – Year over year growth 2018-2022 (%)
Exhibit 20: Market opportunity by RoA
Exhibit 21: Global alpha-1 antitrypsin drugs market – Customer landscape
Exhibit 22: Global alpha-1 antitrypsin drugs market – Market share by geography 2017-2022 (%)
Exhibit 23: Global alpha-1 antitrypsin drugs market – Regional comparison
Exhibit 24: Americas – Market size and forecast 2017-2022 ($ mn)
Exhibit 25: Americas – Year-over-year growth 2018-2022 (%)
Exhibit 26: EMEA – Market size and forecast 2017-2022 ($ mn)
Exhibit 27: EMEA – Year-over-year growth 2018-2022 (%)
Exhibit 28: APAC – Market size and forecast 2017-2022 ($ mn)
Exhibit 29: APAC – Year-over-year growth 2018-2022 (%)
Exhibit 30: Global alpha-1 antitrypsin drugs market – Market opportunity
Exhibit 31: Vendor landscape
Exhibit 32: Landscape disruption
Exhibit 33: Vendors covered
Exhibit 34: Vendor classification
Exhibit 35: Market positioning of vendors
Exhibit 36: CSL overview
Exhibit 37: CSL – Business segments
Exhibit 38: CSL – Organizational developments
Exhibit 39: CSL – Geographic focus
Exhibit 40: CSL – Segment focus
Exhibit 41: CSL – Key offerings
Exhibit 42: GRIFOLS overview
Exhibit 43: GRIFOLS – Business segments
Exhibit 44: GRIFOLS – Organizational developments
Exhibit 45: GRIFOLS – Geographic focus
Exhibit 46: GRIFOLS – Segment focus
Exhibit 47: GRIFOLS – Key offerings
Exhibit 48: Kamada overview
Exhibit 49: Kamada – Business segments
Exhibit 50: Kamada – Organizational developments
Exhibit 51: Kamada – Segment focus
Exhibit 52: Kamada – Key offerings
Exhibit 53: Shire – overview
Exhibit 54: Shire – Business segments
Exhibit 55: Shire – Organizational developments
Exhibit 56: Shire – Geographic focus
Exhibit 57: Shire – Segment focus
Exhibit 58: Shire – Key offerings



【掲載企業】

Shire, CSL, GRIFOLS, and Kamada

★調査レポート[α1-アンチトリプシン薬の世界市場2018-2022] (Global Alpha-1 Antitrypsin Drugs Market 2018-2022 / IRTNTR21835)販売に関する免責事項
[α1-アンチトリプシン薬の世界市場2018-2022] (Global Alpha-1 Antitrypsin Drugs Market 2018-2022 / IRTNTR21835)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆